An observational study in ALS and ALS (Amyotrophic Lateral Sclerosis), sponsored by Viome. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-05.
Sponsored by Viome · Observational
The goal of this observational study is to identify molecular features in multiple clinical samples and/or the patient environment that are associated with ALS. Participants will collect biological samples and answer questionnaires regarding their health at each appointment with their ALS practitioner.
978 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 277 are open to participants now.
This study's planned enrollment of 20 is below the median of 108 across 265 observational studies indexed under Amyotrophic Lateral Sclerosis.
Browse Amyotrophic Lateral Sclerosis studies →Viome is the lead sponsor of 25 studies on the registry; 13 are open to participants now.
Counted across the registry records on this site, refreshed daily.
ALS cohort: Patients of Dr. Espíndola at UFSC Control cohort: Participants from the general population
Exclusion Criteria:
-
Patients of Dr. Espíndola at UFSC that are diagnosed with ALS and meet the inclusion/exclusion criteria.
Those that meet the inclusion/exclusion criteria, do not have ALS, and generally are healthy.
Molecular features of biological samples that are predictive of ALS progression
Time frame: We will collect samples and health data from each participant from the time of diagnosis to their death or study termination, whichever comes sooner. Specific time frame: We will collect outcome measures through study completion, an average of 3 years.
No study locations are listed for this record.
Start is estimated for Jun 2025; primary completion for Feb 2030, 56 months later.
Of 136 observational studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 114. This study's planned 56 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Amyotrophic Lateral Sclerosis →